Previous genomic analysis of stage 4 pediatric neuroblastoma samples identified ATRX mutations occurred among patients who were typically older than 5 years of age, had an indolent disease course, and poor overall survival (OS) (Cheung et al., 2012; Cheung and Dyer, 2013; Mossé et al., 2014). The gene discussed is ATRX; the disease is neuroblastoma.